Funds used to advance lomitapide; Jefferies and Deutsche Bank assist
By Toni Weeks
San Diego, June 24 - Aegerion Pharmaceuticals, Inc. said it priced a $65.88 million public sale of stock with a $9.88 million greenshoe for 637,500 shares.
The company will sell 4.25 million common shares at $15.50 apiece. Of the shares, 3.25 million are being offered by Aegerion and 1 million by selling stockholders. The price per share is a 0.32% discount to the $15.55 closing share price on June 23.
Jefferies & Co., Inc. and Deutsche Bank Securities Inc. are the joint bookrunning managers. Leerink Swann LLC, Needham & Co., LLC and Collins Stewart LLC are the co-managers.
Proceeds will be used to advance the clinical development of the drug lomitapide, including preparing and submitting its New Drug Application, completing its phase III clinical trial and commercially launching the drug. Proceeds will also be used for working capital, capital expenditures and other general corporate purposes.
The specialty pharmaceutical company is based in Cambridge, Mass.
| Issuer: | Aegerion Pharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $65,875,000
|
| Greenshoe: | $9,881,250 (637,500 shares)
|
| Shares: | 4.25 million
|
| Price: | $15.50
|
| Warrants: | No
|
| Managers: | Jefferies & Co., Inc. and Deutsche Bank Securities Inc. (joint bookrunning managers); Leerink Swann LLC, Needham & Co., LLC and Collins Stewart LLC (co-managers)
|
| Pricing date: | June 24
|
| Stock symbol: | Nasdaq: AEGR
|
| Stock price: | $15.55 at close June 23
|
| Market capitalization: | $264.09 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
